Overview

A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in Healthy Adult Male Volunteers

Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose (MTD) and assess safety and tolerability of escalating single doses of TransCon PEG treprostinil administered as a subcutaneous injection to healthy male volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Ascendis Pharma A/S
Treatments:
Treprostinil